Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.54 |
| ▸ | GSPT1 | P15170 | 7/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61273 | 0.94 | CRBN (0.62) | CRBNGSPT1IKZF3DDB1CSNK1A1 | |
| SCHEMBL23240034 | 0.86 | CRBN (0.62) | CRBNGSPT1IKZF3DDB1CSNK1A1 | |
| SCHEMBL27290411 | 0.85 | CRBN (0.57) | CRBNGSPT1IKZF3DDB1CSNK1A1 | |
| SCHEMBL23240032 | 0.85 | CRBN (0.64) | CRBNGSPT1IKZF3DDB1CSNK1A1 | |
| SCHEMBL23239968 | 0.84 | CRBN (0.57) | CRBNGSPT1IKZF3DDB1CSNK1A1 | |
| SCHEMBL60831 | 0.84 | CRBN (0.68) | CRBNGSPT1IKZF3DDB1CSNK1A1 | |
| SCHEMBL23240004 | 0.83 | CRBN (0.56) | CRBNGSPT1IKZF3DDB1CSNK1A1 | |
| SCHEMBL23213339 | 0.83 | CRBN (0.63) | CRBNGSPT1IKZF3DDB1CSNK1A1 | |
| SCHEMBL23240044 | 0.83 | CRBN (0.63) | CRBNGSPT1IKZF3DDB1CSNK1A1 | |
| SCHEMBL23240227 | 0.83 | CRBN (0.63) | CRBNGSPT1IKZF3DDB1CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | CRBN 524/4885GSPT1 1795/4885IKZF3 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.